Transcatheter aortic valve implantation: Single center experience with mid-term follow-up

BackgroundTranscatheter aortic-valve implantation (TAVI) is an emerging intervention for the treatment of high-risk patients with severe aortic stenosis and coexisting illnesses.MethodsBetween August 2009 and May 2012, we have conducted a retrospective study underwent a balloon expandable transcatheter xenograft (Edwards SAPIEN®) and evaluated the intermediate-term all cause mortality. Average STS and EuroSCORE II predicted risk for mortality was 18.4±8.9% and 7.6±5.5%, respectively. The end points included feasibility, safety, efficacy, and durability.ResultsA total of 27 consecutive patients underwent TAVI. Nine (33.3%) patients among them had it through the trans-apical approach. The mean age was 76±8 years; 41% of the patients were females. There was 100% successful implantation. Hospital and one-year mortality were 2 (7.4%) and 4 (14.8%), respectively. At 1 year, the incidence of stroke was 1 (3.7%), infection 6 (22%), AV block 2 (7.4%), severe bleeding 2 (7.4%), vascular complication (14.8%), and the incidence of periprosthetic aortic regurgitation (